Literature DB >> 16780913

Ancestral and consensus envelope immunogens for HIV-1 subtype C.

Denise L Kothe1, Yingying Li, Julie M Decker, Frederic Bibollet-Ruche, Kenneth P Zammit, Maria G Salazar, Yalu Chen, Zhiping Weng, Eric A Weaver, Feng Gao, Barton F Haynes, George M Shaw, Bette T M Korber, Beatrice H Hahn.   

Abstract

Immunogens based on "centralized" (ancestral or consensus) HIV-1 sequences minimize the genetic distance between vaccine strains and contemporary viruses and should thus elicit immune responses that recognize a broader spectrum of viral variants. However, the biologic, antigenic and immunogenic properties of such inferred gene products have to be validated experimentally. Here, we report the construction and characterization of the first full-length ancestral (AncC) and consensus (ConC) env genes of HIV-1 (group M) subtype C. The codon-usage-optimized genes expressed high levels of envelope glycoproteins that were incorporated into HIV-1 virions, mediated infection via the CCR5 co-receptor and retained neutralizing epitopes as recognized by plasma from patients with chronic HIV-1 subtype C infection. Guinea pigs immunized with AncC and ConC env DNA developed high titer binding, but no appreciable homologous or heterologous neutralizing antibodies. When tested by immunoblot analysis, sera from AncC and ConC env immunized guinea pigs recognized a greater number of primary subtype C envelope glycoproteins than sera from guinea pigs immunized with a contemporary subtype C env control. Mice immunized with AncC and ConC env DNA developed gamma interferon T cell responses that recognized overlapping peptides from the cognate ConC and a heterologous subtype C Env control. Thus, both AncC and ConC env genes expressed functional envelope glycoproteins that were immunogenic in laboratory animals and elicited humoral and cellular immune responses of comparable breadth and magnitude. These results establish the utility of centralized HIV-1 subtype C Env immunogens and warrant their continued evaluation as potential components of future AIDS vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16780913     DOI: 10.1016/j.virol.2006.05.011

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  59 in total

1.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

2.  Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Authors:  Jiri Mestecky; Peter F Wright; Lucia Lopalco; Herman F Staats; Pamela A Kozlowski; Zina Moldoveanu; Rashada C Alexander; Rose Kulhavy; Claudia Pastori; Leonard Maboko; Gabriele Riedner; Yuwei Zhu; Terri Wrinn; Michael Hoelscher
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-22       Impact factor: 2.205

Review 3.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

Review 4.  T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Authors:  Bette T Korber; Norman L Letvin; Barton F Haynes
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

5.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

6.  A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys.

Authors:  Sampa Santra; Bette T Korber; Mark Muldoon; Dan H Barouch; Gary J Nabel; Feng Gao; Beatrice H Hahn; Barton F Haynes; Norman L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

7.  HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.

Authors:  Lifei Yang; Yufeng Song; Xiaomin Li; Xiaoxing Huang; Jingjing Liu; Heng Ding; Ping Zhu; Paul Zhou
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

8.  Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Authors:  Catherine A Blish; D Noah Sather; George Sellhorn; Leonidas Stamatatos; Yide Sun; Indresh Srivastava; Susan W Barnett; Brad Cleveland; Julie Overbaugh; Shiu-lok Hu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

9.  A lectin isolated from bananas is a potent inhibitor of HIV replication.

Authors:  Michael D Swanson; Harry C Winter; Irwin J Goldstein; David M Markovitz
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

Review 10.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.